Unifyline Syrup Uses

Unifyline is a bronchodilator medication that is primarily used for the management of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). It is mostly recommended for children and adults where a low dose of medicine is needed. The following are some common uses and indications of Unifyline Syrup:

1. Asthma: Unifyline syrup is used to treat the symptoms of asthma, such as shortness of breath, wheezing, and coughing.
2. Chronic Obstructive Pulmonary Disease (COPD): Unifyline syrup is used to treat the symptoms of COPD, such as shortness of breath, wheezing, and coughing.
3. Bronchitis: Unifyline syrup is used to treat bronchitis, which is an inflammation of the airways in the lungs.
4. Emphysema: Unifyline syrup is used to treat emphysema, which is a lung disease that causes damage to the air sacs in the lungs.

Off-label Uses of Unifyline Syrup

1. Cough: Unifyline syrup may be used off-label to help alleviate cough symptoms in certain cases. It may be considered when other treatments have been ineffective or when the cough is associated with conditions such as bronchitis or chronic cough.
2. Allergic Rhinitis: Although not a primary indication, Unifyline syrup may be used off-label in the management of allergic rhinitis, which is characterized by symptoms such as sneezing, itching, and a runny or blocked nose due to allergic reactions.
3. Bronchiectasis: Unifyline syrup may be used off-label in the treatment of bronchiectasis, a condition characterized by permanent dilation and damage to the bronchial tubes. It can help improve lung function and reduce symptoms such as cough, mucus production, and shortness of breath.

Unifyline Syrup is one of the leading brands of Doxofylline in oral liquid form, manufactured and marketed by Platimu, Pharmaceuticals (Pvt) Ltd, Pakistan.

Here are Some alternative brands of Unifyline Syrup and their manufacturers.

• Ofylin : Continental Pharmaceuticals, Pakistan.
• Fylod : Sami Pharmaceuticals (Pvt) Ltd, Pakistan.
• Doxolin : Novartis Phama (Pakistan) Ltd.
• Agolix : Hiranis Pharmaceuticals (Pvt) Ltd, Pakistan.
• Xofyl : Tabros Pharma Pakistan.
• Maxfyl : Neutro Pharma (Pvt) Ltd, Pakistan.
• Dowfylin : Martin Dow (Pvt) Ltd, Pakistan.
• Xanthofyl : Nabiqasim Industries (Pvt) Ltd, Pakistan.
• Phylin : Genix Pharmaceuticals (Pvt) Ltd, Pakistan.
• Profylline : Kaizen Pharmaceuticals (Pvt) Ltd, Pakistan.

Presently, Unifyline is available in Syrup and Tablet forms.

Unifyline Syrup : 100mg/5ml strength.

Unifyline Tablet : 400mg strength.

Unifyline syrup, like any medication, has certain contraindications. Contraindications are specific situations or conditions in which the use of Unifyline is not recommended or should be avoided.

Hypersensitivity: Unifyline syrup should not be used in individuals who have a known hypersensitivity or allergic reaction to Unifyline or any of its components. Allergic reactions to Unifyline can range from mild skin reactions to severe allergic reactions.

Severe cardiac arrhythmias: Unifyline syrup is contraindicated in individuals with severe cardiac arrhythmias, such as ventricular arrhythmias or atrial fibrillation, as it may exacerbate these conditions.

Acute myocardial infarction: Unifyline syrup should be avoided in individuals who have recently experienced an acute myocardial infarction (heart attack), as it may increase the workload on the heart.

Uncontrolled epilepsy: Unifyline syrup is contraindicated in individuals with uncontrolled epilepsy, as it may lower the seizure threshold and potentially increase the risk of seizures.

Severe hepatic impairment: Unifyline syrup should be used with caution or avoided in individuals with severe liver impairment, as the clearance of the medication may be reduced.

Unifyline Syrup Dose for Adults and Adolescents (above 12 years):

• 10 ml (2 teaspoons) two to three times daily.

Unifyline Syrup Dose for Children (6 to 11 years):

• 5 ml (1 teaspoon) two to three times daily.

Unifyline Syrup Dose for Children (2 to 5 years):

• 2.5 ml (half a teaspoon) two to three times daily.

Unifyline is a medication that belongs to the xanthine derivative class and has bronchodilator properties. While the exact mode of action of Unifyline is not fully understood, it is believed to work through several mechanisms:

Phosphodiesterase Inhibition: Unifyline inhibits phosphodiesterase enzymes, particularly phosphodiesterase-4 (PDE4). By inhibiting PDE4, it increases the levels of intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP levels help relax the smooth muscles lining the airways, leading to bronchodilation and improved airflow.

Adenosine Receptor Antagonism: Unifyline acts as an antagonist at the adenosine receptors, particularly the adenosine A1 and A2A receptors. Adenosine is a naturally occurring substance in the body that can cause bronchoconstriction and airway inflammation. By blocking the adenosine receptors, Unifyline helps prevent the constriction of airway smooth muscles, leading to bronchodilation.

Anti-inflammatory Effects: Unifyline has been shown to possess anti-inflammatory properties. It reduces the release of pro-inflammatory substances, such as cytokines and leukotrienes, which can contribute to airway inflammation and bronchoconstriction.